Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
about
Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
P2860
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@en
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@nl
type
label
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@en
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@nl
prefLabel
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@en
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
@nl
P2093
P2860
P50
P1476
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma
@en
P2093
Anthony T C Chan
Cecilia P Y Lau
Connie W C Hui
Stephen L Chan
P2860
P2888
P304
P356
10.1007/S00280-013-2139-4
P577
2013-04-02T00:00:00Z